{
    "clinical_study": {
        "@rank": "131090", 
        "acronym": "AIDA", 
        "arm_group": [
            {
                "arm_group_label": "ABSORB BVS\u2122", 
                "arm_group_type": "Active Comparator", 
                "description": "Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System"
            }, 
            {
                "arm_group_label": "XIENCE\u2122", 
                "arm_group_type": "Active Comparator", 
                "description": "XIENCE PRIME everolimus eluting coronary stent system and the XIENCE Xpedition everolimus eluting coronary stent system"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and performance in an all-comers contemporary population of the\n      ABSORB bioresorbable vascular scaffolds (BVS) strategy versus the XIENCE family (XIENCE\n      PRIME or XIENCE Xpedition) everolimus eluting coronary stent system in the treatment of\n      coronary lesions."
        }, 
        "brief_title": "Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial", 
        "completion_date": {
            "#text": "August 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Artery Disease", 
            "Myocardial Infarction"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "The AIDA trial is a prospective, randomized (1:1), active control, single blinded,\n      two-center, all-comers, non-inferiority trial. A total of 2670 subjects will be enrolled\n      with broad inclusion and limited exclusion criteria. The study population will include both\n      simple and complex lesions, as well as stable and acute coronary syndrome patients. The\n      follow-up will continue for 5 years including clinical endpoint characteristics."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is an acceptable candidate for treatment with a drug-eluting stent in\n             accordance with the applicable guidelines on percutaneous coronary interventions and\n             the Instructions for Use of the ABSORB BVS strategy and XIENCE family.\n\n          -  Subject is able to verbally confirm understanding of risks, benefits and treatment\n             alternatives of receiving the ABSORB BVS strategy and he/she or his/her legally\n             authorized representative provides written informed consent prior to any Clinical\n             Investigation related procedure, as approved by the appropriate Ethics Committee.\n\n        Exclusion Criteria:\n\n          -  Subject is younger than 18 years of age\n\n          -  Subject has a true bifurcation lesion where a priori two scaffold/stent strategy is\n             planned.\n\n          -  Unsuccessful predilation of one or more of the planned lesion to be treated.\n\n          -  Planned treatment of in-stent restenosis of a previously placed metallic stent.\n\n          -  Subject has one or more lesion planned to be treated with a scaffold/stent diameter\n             size smaller than 2.5 mm or greater than 4.0 mm.\n\n          -  Subject has one or more lesion planned to be treated with a stent/scaffold length\n             greater than 70 mm and/or overlapping of four or more scaffolds/stents.\n\n          -  Subject has known hypersensitivity or contraindication to aspirin, both heparin and\n             bivalirudin, antiplatelet medication specified for use in the study (clopidogrel,\n             prasugrel and ticagrelor, inclusive), everolimus, poly (L-lactide), poly\n             (DL-lactide), cobalt, chromium, nickel, tungsten, acrylic and fluoro polymers or\n             contrast sensitivity that cannot be adequately pre-medicated.\n\n          -  Subjects pregnant or nursing subjects and those who plan pregnancy in the period up\n             to 2 years following index procedure. (Female subjects of child-bearing potential\n             must have a negative pregnancy test done within 28 days prior to the index procedure\n             and contraception must be used during participation in this trial)\n\n          -  Subjects with a limited life expectancy less than one year.\n\n          -  Subjects with factors that impede clinical follow-up (e.g. no fixed abode).\n\n          -  Subject is already participating in another clinical investigation that has not yet\n             reached its primary endpoint.\n\n          -  Subject is belonging to a vulnerable population (per investigator's judgment, e.g.,\n             subordinate hospital staff or sponsor staff) or subject unable to read or write."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2670", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01858077", 
            "org_study_id": "COR 10341", 
            "secondary_id": "AIDA trial"
        }, 
        "intervention": [
            {
                "arm_group_label": "ABSORB BVS\u2122", 
                "intervention_name": "ABSORB BVS\u2122", 
                "intervention_type": "Device", 
                "other_name": [
                    "ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold", 
                    "ABSORB", 
                    "ABSORB BVS", 
                    "BVS"
                ]
            }, 
            {
                "arm_group_label": "XIENCE\u2122", 
                "intervention_name": "XIENCE\u2122", 
                "intervention_type": "Device", 
                "other_name": [
                    "XIENCE PRIME", 
                    "XIENCE Xpedition", 
                    "XIENCE", 
                    "DES", 
                    "Drug eluting stent"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 4, 2013", 
        "location": {
            "contact": {
                "email": "j.j.Wykrzykowska@amc.uva.nl", 
                "last_name": "Joanna Wykrzykowska", 
                "phone": "020 - 566 9111"
            }, 
            "facility": {
                "address": {
                    "city": "Amsterdam", 
                    "country": "Netherlands", 
                    "state": "Noord-Holland", 
                    "zip": "1105 AZ"
                }, 
                "name": "AMC"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial (AIDA Trial): A Clinical Evaluation Comparing the Efficacy and Performance of ABSORB\u2122 Everolimus Eluting Bioresorbable Vascular Scaffold Strategy Versus the XIENCE Family (XIENCE PRIME\u2122 or XIENCE Xpedition\u2122) Everolimus Eluting Coronary Stent Strategy in the Treatment of Coronary Lesions in Consecutive All-comers.", 
        "overall_contact": {
            "email": "j.j.wykrzykowska@amc.uva.nl", 
            "last_name": "Joanna Wykrzykowska, MD, PhD", 
            "phone": "020 - 566 9111"
        }, 
        "overall_contact_backup": {
            "email": "r.p.kraak@amc.uva.nl", 
            "last_name": "Robin Kraak, MD"
        }, 
        "overall_official": [
            {
                "affiliation": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
                "last_name": "Joanna Wykrzykowska, MD, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
                "last_name": "Rob de Winter, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
                "last_name": "Jan Piek, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
                "last_name": "Jose Henriques, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: Medical Ethics Review Committee (METC)", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary composite endpoint is the device-oriented composite of target vessel failure (TVF):\nCardiac death\nMyocardial Infarction (MI) (unless clearly attributable to a non target vessel)\nTarget vessel revascularization", 
            "measure": "Target Vessel Failure (TVF)", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "reference": [
            {
                "PMID": "23517836", 
                "citation": "Muramatsu T, Onuma Y, Garc\u00eda-Garc\u00eda HM, Farooq V, Bourantas CV, Morel MA, Li X, Veldhof S, Bartorelli A, Whitbourn R, Abizaid A, Serruys PW; ABSORB-EXTEND Investigators. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. JACC Cardiovasc Interv. 2013 Mar;6(3):247-57. doi: 10.1016/j.jcin.2012.10.013."
            }, 
            {
                "PMID": "23137495", 
                "citation": "Diletti R, Serruys PW, Farooq V, Sudhir K, Dorange C, Miquel-Hebert K, Veldhof S, Rapoza R, Onuma Y, Garcia-Garcia HM, Chevalier B. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J. 2012 Nov;164(5):654-63. doi: 10.1016/j.ahj.2012.08.010."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01858077"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
            "investigator_full_name": "J.J. Wykrzykowska", 
            "investigator_title": "J.J. Wykrzykowska, MD, PhD, Coordinating Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Successful delivery and deployment of the first study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 20% by quantitative coronary angiography (QCA) and thrombolysis in myocardial infarction (TIMI) 3 flow grade of the treated vessel.", 
                "measure": "Device success", 
                "safety_issue": "Yes", 
                "time_frame": "1 day"
            }, 
            {
                "description": "Achievement of final in-scaffold/stent residual stenosis of less than 20% by QCA and TIMI 3 flow grade of the treated vessel with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat Target Lesion Revascularization during the hospital stay.", 
                "measure": "Procedural success", 
                "safety_issue": "Yes", 
                "time_frame": "1 day"
            }, 
            {
                "description": "Cardiac death, MI (not clearly attributable to a nontarget vessel) or target vessel revascularization", 
                "measure": "Target vessel failure (TVF)", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, and 1, 3, 4 and 5 years"
            }, 
            {
                "description": "Cardiac death, MI (not clearly attributable to a nontarget vessel) or target lesion revascularization", 
                "measure": "Target lesion failure", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, and 1, 2, 3, 4 and 5 years"
            }, 
            {
                "measure": "All revascularizations", 
                "safety_issue": "Yes", 
                "time_frame": "5 year"
            }, 
            {
                "description": "All-cause mortality, any MI, any repeat revascularization", 
                "measure": "Major adverse cardiac events", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, and 1, 2, 3, 4 and 5 years"
            }, 
            {
                "measure": "All cause mortality", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 1 year, 2, 3, 4 and 5 years"
            }, 
            {
                "description": "Q-wave Myocardial Infarction (QMI) and non Q-wave Myocardial Infarction (nonQMI)/target-vessel myocardial infarction (TVMI) and non-TVMI", 
                "measure": "Myocardial Infarction", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 1, 2, 3, 4 and 5 years"
            }, 
            {
                "measure": "Target Lesion Revascularization (TLR)", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 1 year, 2, 3, 4 and 5 years"
            }, 
            {
                "measure": "Target Vessel Revascularization (TVR)", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 1 year, 2, 3, 4 and 5 years"
            }, 
            {
                "measure": "Non-Target Vessel Revascularization (NTVR)", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 1 year, 2, 3, 4 and 5 years"
            }, 
            {
                "description": "acute, subacute, late/definite and probable", 
                "measure": "Scaffold/Stent Thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "30 days, 1, 2, 3, 4 and 5 years"
            }, 
            {
                "measure": "Seattle Angina Questionnaire (SAQ)", 
                "safety_issue": "No", 
                "time_frame": "1 year and 2 years"
            }, 
            {
                "measure": "Quality of Life Questionnaire (QOL)", 
                "safety_issue": "No", 
                "time_frame": "1 year and 2 years"
            }
        ], 
        "source": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}